Neuphoria Therapeutics Inc.

NasdaqGM:NEUP Stock Report

Market Cap: US$23.3b

Neuphoria Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NEUP?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders6,749,4920.192%
VC/PE Firms183,121,4415.21%
Institutions257,080,6807.31%
Hedge Funds311,454,5208.86%
General Public2,756,516,73178.4%

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.

Top Shareholders

Top 16 shareholders own 21.58% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.86%
Armistice Capital LLC
311,454,520US$2.1b-0.87%11.78%
5.21%
Apeiron Investment Group
183,121,441US$1.2b0%93.51%
2.81%
Lynx1 Capital Management LP
98,941,140US$656.0m-8.34%0.06%
2.66%
Presight Capital
93,369,060US$619.0m-34.4%1.2%
1.62%
Point72 Asset Management, L.P.
56,880,000US$377.1m0%no data
0.17%
Susquehanna International Group, LLP, Asset Management Arm
6,144,840US$40.7m0%no data
0.17%
Spyridon Papapetropoulos
5,999,940US$39.8m0%no data
0.043%
Rhumbline Advisers Ltd Partnership
1,494,000US$9.9m278%no data
0.0077%
Peter Miles Davies
269,984US$1.8m0%no data
0.0072%
David Wilson
251,939US$1.7m0%no data
0.0046%
Morgan Stanley, Investment Banking and Brokerage Investments
160,920US$1.1m12.6%no data
0.0036%
Elizabeth Doolin
127,629US$845.9k0%no data
0.0029%
Alan Fisher
100,000US$664.2k0%no data
0.0015%
Northwestern Mutual Wealth Management Company
54,540US$361.2k0%no data
0.001%
Aspire Private Capital, LLC
36,000US$237.7k0%no data
0.00001%
JPMorgan Chase & Co, Brokerage and Securities Investments
180US$2.3k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neuphoria Therapeutics Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tanushree JainBell Potter
Esther Lannie HongBerenberg
Charles DuncanCantor Fitzgerald & Co.